Physician profile
Stephanie A Pollitz
NPI 1558362053
$1,677.54
in general payments reported to CMS, 2019-2025
14 companies · $84.99 in 2025
The $84.99 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,198 · 2024: $394 · 2025: $84.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.55 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $394.23 | 2023 | Myrisk |
| Mayne Pharma Commercial LLC | $213.89 | 2023-2024 | |
| Astellas Pharma US INC | $164.88 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $157.27 | 2023-2024 | Myfembree |
| Abbvie INC. | $145.44 | 2023 | |
| Organon LLC | $133.33 | 2023-2024 | Nexplanon |
| Daiichi Sankyo INC. | $133.03 | 2023-2024 | Injectafer |
| Agile Therapeutics, INC. | $111.63 | 2023-2024 | Twirla |
| Merck Sharp & Dohme LLC | $49.85 | 2023-2024 | Gardasil 9, Gardasil |
| Avion Pharmaceuticals | $47.69 | 2023 | Balcoltra |
| Exeltis, USA INC. | $44.15 | 2023-2024 | Slynd |
| Biogen, INC. | $29.16 | 2024 | |
| Coopersurgical, INC. | $28.62 | 2023 | Paragard T 380a |
| Evofem Biosciences, INC. | $24.37 | 2023 | Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Pollitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.